Treatment of hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
VYNDAQEL — FOLDRX PHARMS, approved 2023-10-17 (NDA211996).
12,229 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.